实验猴价格翻倍！AI 重塑创新药行业，A 股/港股/美股生物科技赛道拆解 Lab Monkey Price Surge: How AI Transforms Biotech

A 股市场出现明显分化，科技板块调整，生物医药板块因实验猴供不应求持续走强。实验猴龙头企业业绩大幅预增，根源是全球实验猴缺口庞大。 核心底层逻辑在于 AI 技术革新新药研发，缩短研发时长、吸引大量资本投入，生物医药行业告别过去几年低谷。 横向对比 A 股创新药、港股通创新药、纳斯达克生物科技当前估值历史分位，给出适合普通普通人的长期配置方式，闲钱定投、长期持有。 仅个人分享，非投资建议 The A-share market shows divergence: tech sectors drop while biotech surges due to a massive shortage of lab monkeys. Leading lab monkey firm forecasts huge profit growth, driven by doubled monkey prices worldwide. The core driver behind this trend is AI technology, which drastically cuts drug development timelines and attracts growing capital into AI pharmaceutical research, lifting the whole biotech industry out of its downturn. We compare valuation levels of innovative drug sectors across China A-shares, Hong Kong Stock Connect and Nasdaq biotech index, sharing a long-term low-risk saving strategy for regular people: invest spare money via dollar-cost averaging for long-term holdings. Disclaimer: This video is for personal sharing only, not financial advice.